Zai Lab To Discontinue Development Of ZL-3101 For Atopic Dermatitis

(RTTNews) - Zai Lab Limited (ZLAB) announced the decision to discontinue the development of ZL-3101 (Fugan) for the treatment of atopic dermatitis (AD). This decision was made based on the top-line results of a Phase IIA trial of ZL-3101 in patients with mild to moderate subacute eczema.

The double-blind, randomized, placebo-controlled multi-center Phase IIA study enrolled 295 Chinese patients with AD. Although the study showed that topical ZL-3101 was safe and well-tolerated, the treatment showed no difference compared to placebo in the primary efficacy endpoint, a change in the Eczema Area and Severity Index (EASI) score at day 21.

"Although disappointing, our broad and advanced pipeline enables us to redirect resources allocated to ZL-3101 to our other advanced clinical-stage assets and opportunities," said Samantha Du, Zai Lab's Chief Executive Officer.